# Cholangiocarcinoma and Gallbladder Cancer Studies
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, management, epidemiology, and therapeutic strategies for cholangiocarcinoma, including intrahepatic and hilar cholangiocarcinoma. It covers topics such as surgical management, molecular pathology, and prognostic factors. The papers also discuss the increasing incidence and mortality of biliary tract cancers, as well as emerging targeted therapies. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11364 |
| Works | 530 |
## Topic papers all
Showing 15 of 530.
- [Comprehensive molecular characterization of gastric adenocarcinoma](https://scholariq.org/papers/comprehensive-molecular-characterization-of-gastric-adenocarcinoma/)
- [A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer](https://scholariq.org/papers/a-randomized-trial-of-chemoradiotherapy-and-chemotherapy-after-resection-of/)
- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Cholangiocarcinoma 2020: the next horizon in mechanisms and management](https://scholariq.org/papers/cholangiocarcinoma-2020-the-next-horizon-in-mechanisms-and-management/)
- [Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma](https://scholariq.org/papers/integrated-genomic-characterization-of-pancreatic-ductal-adenocarcinoma/)
- [Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis](https://scholariq.org/papers/predicting-survival-after-liver-transplantation-in-patients-with-hepatocellular/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib](https://scholariq.org/papers/i-met-i-amplification-occurs-with-or-without-i-t790m-i-mutations-in-i-egfr-i/)
- [Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos)](https://scholariq.org/papers/tokyo-guidelines-2018-diagnostic-criteria-and-severity-grading-of-acute/)
- [Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)](https://scholariq.org/papers/adjuvant-chemotherapy-of-s-1-versus-gemcitabine-for-resected-pancreatic-cancer-a/)
- [A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients](https://scholariq.org/papers/a-unique-metastasis-gene-signature-enables-prediction-of-tumor-relapse-in-early/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes](https://scholariq.org/papers/radioembolization-for-hepatocellular-carcinoma-using-yttrium-90-microspheres-a/)
- [Preoperative Biliary Drainage for Cancer of the Head of the Pancreas](https://scholariq.org/papers/preoperative-biliary-drainage-for-cancer-of-the-head-of-the-pancreas/)
- [FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis](https://scholariq.org/papers/folfirinox-for-locally-advanced-pancreatic-cancer-a-systematic-review-and/)
## Topic primary papers
Showing 15 of 126.
- [Comprehensive molecular characterization of gastric adenocarcinoma](https://scholariq.org/papers/comprehensive-molecular-characterization-of-gastric-adenocarcinoma/)
- [Cholangiocarcinoma 2020: the next horizon in mechanisms and management](https://scholariq.org/papers/cholangiocarcinoma-2020-the-next-horizon-in-mechanisms-and-management/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial](https://scholariq.org/papers/second-line-folfox-chemotherapy-versus-active-symptom-control-for-advanced/)
- [Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment](https://scholariq.org/papers/intrahepatic-cholangiocarcinoma-an-international-multi-institutional-analysis-of/)
- [Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma](https://scholariq.org/papers/liver-transplantation-with-neoadjuvant-chemoradiation-is-more-effective-than/)
- [Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/biliary-tract-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma](https://scholariq.org/papers/polyclonal-secondary-i-fgfr2-i-mutations-drive-acquired-resistance-to-fgfr/)
- [Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-brafv600e-mutated-biliary-tract/)
- [Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project](https://scholariq.org/papers/clinical-significance-of-four-molecular-subtypes-of-gastric-cancer-identified-by/)
- [Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway](https://scholariq.org/papers/whole-exome-and-targeted-gene-sequencing-of-gallbladder-carcinoma-identifies/)
- [Mutational landscape of intrahepatic cholangiocarcinoma](https://scholariq.org/papers/mutational-landscape-of-intrahepatic-cholangiocarcinoma/)
- [The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin](https://scholariq.org/papers/the-clinicopathological-and-prognostic-relevance-of-cytokeratin-7-and-19/)
- [Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma](https://scholariq.org/papers/proteogenomic-characterization-identifies-clinically-relevant-subgroups-of/)
- [Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma](https://scholariq.org/papers/clinicopathological-and-prognostic-significance-of-egfr-vegf-and-her2-expression/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.